Pharmaceuticals
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. 
Subscribe to this data using MyMedWorm.
Subscribe to this data using GoogleReader.
Subscribe to this data using Bloglines.
Subscribe to this data using MyYahoo.
Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.
This page shows you the most recent publications within this specialty of the MedWorm directory. This is page number 3.
AstraZeneca Submits US New Drug Application for Brilinta (Ticagrelor)
Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
AstraZeneca today announced it has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for ticagrelor, an investigational oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndrome (ACS). The proposed trade name for ticagrelor is BRILINTA, pending approval from the FDA.
Source: World Pharma News - November 19, 2009 Category: Pharmaceuticals Source Type: news
GSK and Nabi announce agreement for NicVAX®, a vaccine for nicotine addictionEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
GlaxoSmithKline Biologicals SA (GSK) and Nabi Biopharmaceuticals (Nabi) announcedan exclusive worldwide option and licensing agreement for a nicotine conjugate candidate vaccine (NicVAX®), an investigational vaccine for the treatment of nicotine addiction and the prevention of smoking relapse, as well as for the development of a second generation nicotine vaccine.
Source: World Pharma News - November 19, 2009 Category: Pharmaceuticals Source Type: news
Wright Medical Group, Inc. Announces Initial Release of the VALOR Ankle Fusion Nail SystemEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
New Foot & Ankle Product Solidifies Wrights Market-Leadership in Products for Surgical Treatment of Hindfoot Arthritis
ARLINGTON, Tenn.--(HSMN NewsFeed)--Wright Medical Group, Inc. (NASDAQ: WMGI ), a global orthopaedic medical device company, today ann... Devices, OrthopaedicWright Medical Group, VALOR Ankle Fusion Nail,
Source: HSMN NewsFeed - November 18, 2009 Category: Pharmaceuticals Source Type: news
New Updates to AHA/ACC/SCAI Clinical Guidelines Recommend Treatment with Effient(R) for Patients with Acute Coronary Syndromes Managed with PCIEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
PARSIPPANY, N.J. and INDIANAPOLIS, Nov. 18 (HSMN NewsFeed) -- Effient® (prasugrel) tablets, a new antiplatelet medicine, was added as a treatment option in two clinical guideline updates: one for patients receiving percutaneous coronary intervention ... Biopharmaceuticals, CardiologyEli Lilly, Effient, prasugrel, antiplatelet, STEMI
Source: HSMN NewsFeed - November 18, 2009 Category: Pharmaceuticals Source Type: news
Property concerns prompt NHS probeEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
An inquiry is being opened into how far the health service should retain control of its property when it puts services out to tender or allows mergers and takeovers
Source: FT.com - Drugs and Healthcare - November 18, 2009 Category: Pharmaceuticals Source Type: news
Holy Cross will return Rothstein donationEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Holy Cross Hospital said it intends to return a $1 million donation from embattled Fort Lauderdale attorney Scott Rothstein’s foundation.
Source: bizjournals.com Health Care:Pharmaceuticals headlines - November 18, 2009 Category: Pharmaceuticals Source Type: journals
CBO: Senate Health Bill Costs $849 BillionEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Senate Democrats' health-care legislation has been estimated to cost $849 billion and to reduce the federal budget deficit by $127 billion over 10 years.
Source: WSJ.com: Health - November 18, 2009 Category: Pharmaceuticals Tags: FREE Source Type: news
Kaiser Permanente Selects Silver&Fit(R) Senior Fitness Program for More Than 50,000 KP Senior Advantage (HMO) Members in Oregon and WashingtonEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
SAN DIEGO, Nov. 18, 2009 (GLOBE NEWSWIRE) -- American Specialty Health Incorporated (ASH), one of the nation's leading health and wellness organizations, announced that the Kaiser Permanente Northwest Region has selected its Silver&Fit(R) senior fitness and healthy aging program for over 50,000 individual* and group KP Senior Advantage Medicare members in 15 counties in Oregon and Washington states.
Source: Medical News (via PRIMEZONE) - November 18, 2009 Category: Pharmaceuticals Source Type: news
Sebelius Statement on New Breast Cancer RecommendationsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
WASHINGTON--(HSMN NewsFeed)--HHS Secretary Kathleen Sebelius issued the following statement today on new breast cancer screening recommendations from the U.S. Preventive Services Task Force:
There is no question that the U.S. Preventive Services Task F... Devices, Oncology, Radiologymammogram, mammography, breast cancer
Source: HSMN NewsFeed - November 18, 2009 Category: Pharmaceuticals Source Type: news
Applied Spine Technologies' Stabilimax(R) Dynamic Spine System selected as "Best New Technology for 2009"Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Panel of 30 Independent Surgeon Judges Recognize Stabilimax in the Motion Preservation Category at the 2009 Spine Technology Awards
ROCKY HILL, Conn.--(HSMN NewsFeed)--Applied Spine Technologies, Inc. (www.appliedspine.com), a medical device company foc... Devices, Orthopaedic, NeurosurgeryApplied Spine Technologies, Stabilimax, motion preservation
Source: HSMN NewsFeed - November 18, 2009 Category: Pharmaceuticals Source Type: news
Synta Presents Preclinical Data on Next Generation Hsp90 Inhibitor, STA-9090Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
- Broad anti-cancer activity as a single agent and in
combination
- Strong potency against highly resistant cancers
- Superior profile to first generation Hsp90
inhibitors
LEXINGTON, Mass.--(BUSINESS WIRE)--Nov 18, 2009 -...
Source: Drugs.com - Clinical Trials - November 18, 2009 Category: Pharmaceuticals Source Type: clinical trials
Advocat Announces Details of First Annual Investor DayEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
BRENTWOOD, Tenn., Nov. 18, 2009 (GLOBE NEWSWIRE) -- Advocat Inc. (Nasdaq:AVCA) today announced the agenda for its first annual Investor Day to be held at company headquarters in Brentwood, Tennessee, on Monday, December 7th.
Source: Medical News (via PRIMEZONE) - November 18, 2009 Category: Pharmaceuticals Source Type: news
Synta Presents New Data on Mechanism of Action of Elesclomol at AACR-NCI-EORTC Conference on Molecular Targets and Cancer TherapeuticsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Copper redox reaction key to elesclomol's ability to generate
ROS
LEXINGTON, Mass.--(BUSINESS WIRE)--Nov 18, 2009 - Synta
Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company
focused on discovering, developing, and...
Source: Drugs.com - Clinical Trials - November 18, 2009 Category: Pharmaceuticals Source Type: clinical trials
Graymark Healthcare Reports Third Quarter 2009 ResultsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
OKLAHOMA CITY, Nov. 18, 2009 (GLOBE NEWSWIRE) -- Graymark Healthcare Inc. (Nasdaq:GRMH) today announced results for the third quarter ended September 30, 2009.
Source: Medical News (via PRIMEZONE) - November 18, 2009 Category: Pharmaceuticals Source Type: news
US FDA issues complete response letter for Rituxan/MabThera for chronic lymphocytic leukaemiaEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Roche announced today that the US Food and Drug Administration (FDA) issued a complete response to Genentech, a wholly-owned member of the Roche Group, and Biogen Idec (Nasdaq: BIIB) on the companies’ applications for Rituxan/MabThera (rituximab) plus fludarabine and cyclophosphamide (FC) chemotherapy for the treatment of for the treatment of patients with previously untreated and previously treated chronic lymphocytic leukaemia (CLL).
Source: Roche Investor Update - November 18, 2009 Category: Pharmaceuticals Source Type: organizations
Our Lady of the Lake Connects Infusion Pumps to the EHR to Help Decrease Errors and Improve CareEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
KANSAS CITY, Mo. and LAKE FOREST, Ill., Nov. 18, 2009 (GLOBE NEWSWIRE) -- Helping set the standard for interoperability between medical devices and electronic health records (EHRs), Our Lady of the Lake Regional Medical Center (OLOL) has successfully tested and implemented auto programming between infusion pumps and a bar-code point-of-care system throughout its facility. Through a three-way partnership with Cerner (Nasdaq:CERN) and Hospira, Inc. (NYSE:HSP), OLOL, one of the largest private medical centers in Louisiana, has completed house-wide deployment of a connected medication infusion device, which helps minimize manu...
Source: Medical News (via PRIMEZONE) - November 18, 2009 Category: Pharmaceuticals Source Type: news
Sangamo BioSciences Provides Update on Phase 1 Safety Trial of SB-728-T for HIV/AIDSEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
RICHMOND, Calif., Nov. 18 /PRNewswire-FirstCall/ -- Sangamo
BioSciences, Inc. (NASDAQ:SGMO) announced today that data from the
University of Pennsylvania investigator sponsored Phase 1 safety
study of Sangamo's zinc finger nuclease (ZFN) based...
Source: Drugs.com - Clinical Trials - November 18, 2009 Category: Pharmaceuticals Source Type: clinical trials
Results From Two Phase II Trials Add to Understanding of Ticagrelor (BRILINTA(TM)) and How it Works in the BodyEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Ticagrelor data presented at the American Heart Association
Scientific Sessions
ORLANDO, Fla., Nov. 18 /PRNewswire-FirstCall/ -- AstraZeneca
(NYSE:AZN) today announced the results of the
phase II studies, ONSET/OFFSET and RESPOND for...
Source: Drugs.com - Clinical Trials - November 18, 2009 Category: Pharmaceuticals Source Type: clinical trials
Peregrine Pharmaceuticals Presents Promising Antiviral Data at 2009 Chemical and Biological Defense Science & Technology ConferenceEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
- In Preclinical Studies, Peregrine's PS-Targeting Antibodies
Including Bavituximab Demonstrated Broad Spectrum Binding to
Viruses and Virally Infected Cells Representing Three Viral
Hemorrhagic Fever (VHF) Families - - Preclinical Efficacy...
Source: Drugs.com - Clinical Trials - November 18, 2009 Category: Pharmaceuticals Source Type: clinical trials
Pilots Spring For LessEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Cirrus CEO Brent Wouters on a shift in buying habits sparked by the recession.
Source: Forbes.com Healthcare News - November 18, 2009 Category: Pharmaceuticals Source Type: news
Exelixis Reports Encouraging Phase 1 Data for the PI3K Inhibitor Xl147 (SAR245408) in Combination with Erlotinib at the AACR-NCI-EORTC ConferenceEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
BOSTON--(BUSINESS WIRE)--Nov 18, 2009 - Exelixis, Inc.
(Nasdaq:EXEL) today reported interim data from an ongoing phase 1
dose-escalation trial of XL147 (SAR245408) in combination with the
EGFR inhibitor erlotinib in patients with advanced solid...
Source: Drugs.com - Clinical Trials - November 18, 2009 Category: Pharmaceuticals Source Type: clinical trials
Cardiovascular Outcomes with Ezetimibe and Simvastatin Similar to Statin Alone, Claims Data SuggestEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Retrospective Analysis of Almost 30,000 Patients Shows No
Significant Difference in Risk of Heart Attack or Stroke with
Monotherapy Compared With Combination Therapy
IRVINE, Calif.--(BUSINESS WIRE)--Nov 18, 2009 - Prescription
Solutions, a leading...
Source: Drugs.com - Clinical Trials - November 18, 2009 Category: Pharmaceuticals Source Type: clinical trials
Zydena is Efficacious in Once Daily Dosing for Erectile Dysfunction/Positive BPH ResultsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Data to be presented at 12th Congress of the European Society
for Sexual Medicine, November 15th to 18th, Lyon
SEOUL, South Korea, Nov. 18 /PRNewswire/ -- Dong-A
Pharmaceutical Co., Ltd. and Dong-A PharmTech, Co. Ltd. announced
today that it has...
Source: Drugs.com - Clinical Trials - November 18, 2009 Category: Pharmaceuticals Source Type: clinical trials
Threshold Pharmaceuticals Presents Interim Prostate Cancer Data From Early Stage Trials of TH-302Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Threshold Pharmaceuticals Presents Interim Prostate Cancer Data
From Early Stage Trials of TH-302
REDWOOD CITY, Calif., Nov. 18, 2009 (GLOBE NEWSWIRE) --
Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced
clinical trial results related to...
Source: Drugs.com - Clinical Trials - November 18, 2009 Category: Pharmaceuticals Source Type: clinical trials
Viron reports positive Phase II data in Acute Coronary Syndromes (ACS) patientsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
VT-111 significantly reduces key cardiac enzymes at multiple
time points after stent placement; Data presented at American Heart
Association 2009 Scientific Sessions
LONDON, ON, Nov. 18 /PRNewswire/ -- Viron Therapeutics Inc., a
biotechnology...
Source: Drugs.com - Clinical Trials - November 18, 2009 Category: Pharmaceuticals Source Type: clinical trials
Ex-Pharma Executive Runs as Dem for Kansas GovernorEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
From Associated Press (November 18, 2009)
TOPEKA, Kan.--A former pharmaceutical company executive who
returned to Kansas this year announced Tuesday that he's running
for governor, giving Democrats a declared candidate.
Tom Wiggans, 57, appointed a...
Source: Drugs.com - Pharma News - November 18, 2009 Category: Pharmaceuticals Source Type: news
BSD Medical Corporation Reports Continuation of FDA Review of BSD-2000 Hyperthermia SystemEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
SALT LAKE CITY--(HSMN NewsFeed)--BSD Medical Corporation (NASDAQ: BSDM ) (www.bsdmedical.com) today provided an update on the U.S. Food and Drug Administrations (FDA) review of the Company's Humanitarian Device Exemption (HDE) marketing submission for the... Devices, Oncology, FDABSD Medical, BSD-2000, Hyperthermia
Source: HSMN NewsFeed - November 18, 2009 Category: Pharmaceuticals Source Type: news
Radiation Breakthrough Gives Breast Cancer Patients Hope in Single DoseEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Cancer Treatment Centers of America will be First in Country to Offer New Technology from Italy
PHILADELPHIA, Nov. 18 (HSMN NewsFeed) -- A radiation breakthrough to treat breast cancer patients in one day, as opposed to the current average of six week... Devices, OncologyHitesys, Novac7, Intraoperative Radiotherapy, IORT, radiotherapy
Source: HSMN NewsFeed - November 18, 2009 Category: Pharmaceuticals Source Type: news
EKOS Corporation Launches the New EkoSonic(TM) MACH4e at VEITHsymposium in New YorkEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
No Limits to Treating Thrombus
NEW YORK--(HSMN NewsFeed)--Today EKOS Corporation launched the EkoSonic(TM) MACH4e with Rapid Pulse Modulation (RPM) for the dissolution of vascular blood clots at the 36th Annual VEITHsymposium in New York.
Robert W. H... Devices, InterventionalEKOS Corp, EkoSonic, MACH4e, thrombolysis, VEITHsymposium
Source: HSMN NewsFeed - November 18, 2009 Category: Pharmaceuticals Source Type: news
StemCells, Inc. Provides Update on NCL Program Meeting with FDAEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
PALO ALTO, Calif.--(HSMN NewsFeed)--StemCells, Inc. (NASDAQ: STEM ) today provided an update on the ongoing clinical development program of its proprietary HuCNS-SC(R) product candidate (purified human neural stem cells) for neuronal ceroid lipofuscinosis ... Regenerative Medicine, Neurology, FDAStemCells, HuCNS-SC, neuronal ceroid lipofuscinosis, stem cell
Source: HSMN NewsFeed - November 18, 2009 Category: Pharmaceuticals Source Type: news
InterMune Shares Fall on Change in Hepatitis StudyEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
From Associated Press (November 17, 2009)
NEW YORK--Shares of InterMune Inc. fell Tuesday after the
biotechnology company said it would discontinue a high-dose of its
experimental Hepatitis C treatment in a study because of potential
liver...
Source: Drugs.com - Pharma News - November 18, 2009 Category: Pharmaceuticals Source Type: news
OraSure Technologies Participates in BPAC Meeting on HIV Over-the-Counter TestEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
BETHLEHEM, Pa., Nov. 18, 2009 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that it participated in a Blood Products Advisory Committee ("BPAC") meeting held November 17, 2009 in which the BPAC considered, among other topics, the public need and performance characteristics for over-the-counter ("OTC") home use HIV test kits. The BPAC provides advice to the U.S. Food and Drug Administration ("FDA") on issues related to the safety and effectiveness of biological products and medical devices.
Source: Medical News (via PRIMEZONE) - November 18, 2009 Category: Pharmaceuticals Source Type: news
Pfizer Enters Tropical Disease Drug PartnershipEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
From Associated Press (November 18, 2009)
NEW YORK--Scientists from a not-for-profit foundation will test
150,000 Pfizer Inc. drug candidates as part of a search for
treatments for three tropical diseases that are spread by
insects.
Pfizer and the...
Source: Drugs.com - Pharma News - November 18, 2009 Category: Pharmaceuticals Source Type: news
Netech Corporation Announces the Release of IPA 2000 -- Infusion Pump Analyzer for Fast and Accurate Testing of All Infusion PumpsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Netech Corporation, innovative leader in the manufacture of precision biomedical and industrial test instruments, announces the release of its new Infusion Pump Analyzer, IPA 2000. Utilizing Netech’s patent pending technology; accurate flow rate, volume, and occlusion pressure of any infusion pump can be measured faster than ever before. IPA 2000 is compact and lightweight. This portable device quickly evaluates the operation of infusion devices with both steady and non-steady flow patterns. (PRWeb Nov 18, 2009)
Read the full story at http://www.prweb.com/releases/2009/11/prweb3216474.htm
Source: PRWeb: Medical Pharmaceuticals - November 18, 2009 Category: Pharmaceuticals Source Type: news
NACDS, ROLLSTREAM to Deliver Industry CPSIA Compliance SolutionEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Network to boost effectiveness of compliance. (PRWeb Nov 18, 2009)
Read the full story at http://www.prweb.com/releases/NACDS/RollStream/prweb3220044.htm
Source: PRWeb: Medical Pharmaceuticals - November 18, 2009 Category: Pharmaceuticals Source Type: news
Cerno Bioscience, Agilent Technologies to Co-Market MassWorksTM for GC/MSDEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Calibration software enables single quadrupole instruments to easily identify unknowns. (PRWeb Nov 18, 2009)
Read the full story at http://www.prweb.com/releases/2009/11/prweb3215364.htm
Source: PRWeb: Medical Pharmaceuticals - November 18, 2009 Category: Pharmaceuticals Source Type: news
WellGen Recognized as Nutraceutical “Innovator” by Global Business InsightsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
WellGen has been called out as an innovator by a Global Business Insights industry report. WellGen is developing propeirtary nutraceuticals for medical foods, a market described as a high potential growth area for the future. (PRWeb Nov 18, 2009)
Read the full story at http://www.prweb.com/releases/2009/11/prweb3222434.htm
Source: PRWeb: Medical Pharmaceuticals - November 18, 2009 Category: Pharmaceuticals Source Type: news
Any Lab Test Now® Added to List of HIV & STD Testing Centers in DallasEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Any Lab Test Now® has added themselves to the list of HIV and STD Testing Centers in Dallas (http://anylabtestnorthdallas.com/). Additionally, they are unique in providing affordable and truly anonymous STD screening services to Dallas residents. Any Lab Test Now® is adding HIV and STD testing to their long list of medical lab test results available in 24-48hrs. (PRWeb Nov 18, 2009)
Read the full story at http://www.prweb.com/releases/std-testing-centers/dallas/prweb3224224.htm
Source: PRWeb: Medical Pharmaceuticals - November 18, 2009 Category: Pharmaceuticals Source Type: news
BioSoteria CEO to Present at Drug Safety ConferenceEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
BioSoteria announced that its President and CEO Sally Van Doren, PharmD, will present at the 9th DIA Conference for Contemporary Pharmacovigilance and Risk Management Strategies, which takes place January 10-13, 2010, in Washington, DC. Dr. Van Doren will present on the topic of the Integrated Summary of Safety. (PRWeb Nov 18, 2009)
Read the full story at http://www.prweb.com/releases/pharmacovigilance/conference/prweb3225234.htm
Source: PRWeb: Medical Pharmaceuticals - November 18, 2009 Category: Pharmaceuticals Source Type: news
OCuSOFT Selects rfXcel’s ePedigree SystemEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Ophthalmic Pharmaceutical Leader Chooses rfXcel’s E-Pedigree Management Solution (PRWeb Nov 18, 2009)
Read the full story at http://www.prweb.com/releases/2009/11/prweb3216314.htm
Source: PRWeb: Medical Pharmaceuticals - November 18, 2009 Category: Pharmaceuticals Source Type: news
Datafarm Advances Regulatory Submission Authoring with the Release of S-Cubed® Templates Version 2.0Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Datafarm today announced that S-Cubed Templates version 2.0 offers users major feature enhancements as well as new features including support for Microsoft Word 2007. Regulatory submission document authors have relied on S-Cubed Templates since 2006 to reduce the time manual formatting requires while enabling compliant, multi-agency documents. (PRWeb Nov 17, 2009)
Read the full story at http://www.prweb.com/releases/2009/11/prweb3211294.htm
Source: PRWeb: Medical Pharmaceuticals - November 18, 2009 Category: Pharmaceuticals Source Type: news
Almac Doubles Capacity at North Carolina FacilityEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
The Almac Group has completed a 67,000 square foot expansion to their North Carolina facility in Durham, which now houses both the Clinical Services and Diagnostics Divisions. This additional facility , along with existing capacity, will increase the Durham campus to almost 138,000 square feet and provide 3,000 extra pallet locations for clinical supplies storage requirements. (PRWeb Nov 17, 2009)
Read the full story at http://www.prweb.com/releases/Durhamexpansion/AlmacClinicalServices/prweb3211584.htm
Source: PRWeb: Medical Pharmaceuticals - November 18, 2009 Category: Pharmaceuticals Source Type: news
ConsumerLab.com Finds Many Probiotics Don’t Deliver Listed IngredientsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Many probiotic supplements do not contain the number of viable organisms listed on their labels according to a new report from ConsumerLab.com. At the time a probiotic is purchased it may contain as little as 7% to 58% of the amount listed on its label. Reviews of 29 probiotic products are provided in the new report. (PRWeb Nov 17, 2009)
Read the full story at http://www.prweb.com/releases/2009/11/prweb3213324.htm
Source: PRWeb: Medical Pharmaceuticals - November 18, 2009 Category: Pharmaceuticals Source Type: news
CDPHP® Rated Top Plan In New York State By U.S. News & World Report/NCQA America's Best Health Insurance Plans 2009-10*Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
CDPHP Commercial, HMO, Self-Funded, Medicare, and Medicaid Plans Recognized Among The Nation's Top 25 (PRWeb Nov 17, 2009)
Read the full story at http://www.prweb.com/releases/CDPHP/NCQA/prweb3213634.htm
Source: PRWeb: Medical Pharmaceuticals - November 18, 2009 Category: Pharmaceuticals Source Type: news
Blue Cross Blue Shield of Massachusetts Announces 2010 Medicare OptionsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Seven Plans Offered, Including a Lower Cost PPO (PRWeb Nov 17, 2009)
Read the full story at http://www.prweb.com/releases/2009/11/prweb3213744.htm
Source: PRWeb: Medical Pharmaceuticals - November 18, 2009 Category: Pharmaceuticals Source Type: news
Dr. Randal Pinkett and Lawrence M. Hibbert of BCT Partners Featured in Black EnterpriseEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
The leaders of BCT Partners in Newark, NJ, share in the December issue how re-invention kept their company afloat and thriving among sinking businesses during the recession of 2001. (PRWeb Nov 16, 2009)
Read the full story at http://www.prweb.com/releases/2009/11/prweb3205394.htm
Source: PRWeb: Medical Pharmaceuticals - November 18, 2009 Category: Pharmaceuticals Source Type: news
ThermaFreeze Products Corporation: ThermaFreeze Announces Formation of Majority-Owned Subsidiary American Diversified Medical CorporationEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
MOBILE, AL (MARKET WIRE) ThermaFreeze Products Corporation (PINKSHEETS: TZPC), the maker of patented, innovative refrigerant products designed for use in the commercial shipment of perishables and for use as a consumer compress and chiller product, today announced the formation of a majority-owned subsidiary named American Diversified Medical Corporation (ADM), which will offer products and services to the alternate site healthcare space, specifically homecare and clinics outside of the hospital environment and veterinarian market. ThermaFreeze and ADM plan to announce a portfolio of new therapeutic products called
Source: Market Wire - Pharmaceuticals and Biotech - November 18, 2009 Category: Pharmaceuticals Tags: Pharmaceuticals and Biotech Medical and Healthcare Food and Beverage Retail Manufacturing and Production TZPC Source Type: news
FDA Approves New Post-Shingles Attack DrugEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
From UPI Science News (November 18, 2009)
The U.S. Food and Drug Administration says it has approved a
medicated skin patch that relieves the pain associated with
shingles.
The FDA said the Qutenza
(capsaicin) 8 percent patch treats pain that occurs...
Source: Drugs.com - Pharma News - November 18, 2009 Category: Pharmaceuticals Source Type: news
Tennessee health ranking improves, but obesity loomsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Left unchecked, Tennessee’s obesity epidemic will cost the state $7.08 billion in health care spending over the next decade. That’s $1,442 for every adult, whether obese or not.
Source: bizjournals.com Health Care:Pharmaceuticals headlines - November 18, 2009 Category: Pharmaceuticals Source Type: journals
Nanosphere Announces FDA Submission of 510(k) Documentation for Its Verigene Cardiac Troponin I AssayEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
NORTHBROOK, Ill., Nov. 18, 2009 (GLOBE NEWSWIRE) -- Nanosphere, Inc. (Nasdaq:NSPH), a leader in the development and commercialization of advanced molecular diagnostics systems, announced today it submitted a 510(k) application to the FDA for its cardiac troponin I test that the company believes will provide early and sensitive diagnosis of myocardial infarction and risk stratification for acute coronary syndromes.
Source: Medical News (via PRIMEZONE) - November 18, 2009 Category: Pharmaceuticals Source Type: news
